Sangamo Therapeutics Updates Principal Executive Office Address
Ticker: SGMO · Form: 8-K · Filed: Jan 19, 2024 · CIK: 1001233
| Field | Detail |
|---|---|
| Company | Sangamo Therapeutics, Inc (SGMO) |
| Form Type | 8-K |
| Filed Date | Jan 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $429,820, $193,584 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance
TL;DR
**SGMO just changed its corporate address, no big deal for the stock.**
AI Summary
Sangamo Therapeutics, Inc. (SGMO) filed an 8-K on January 19, 2024, to report a change in its principal executive offices from 7000 Marina Blvd., Brisbane, California 94005 to 501 Canal Blvd., Richmond, California 94084. This change in address is a minor administrative update and does not signal any immediate operational shifts or financial impacts for the company. For investors, this filing primarily serves as a notification of updated contact information, with no direct bearing on the company's stock performance or strategic direction.
Why It Matters
This filing is an administrative update regarding Sangamo Therapeutics' new address and does not indicate any material changes to its business operations, financial health, or strategic direction.
Risk Assessment
Risk Level: low — The filing only reports an administrative change of address, which carries minimal risk to investors.
Analyst Insight
Investors should note this administrative update but recognize it has no direct impact on Sangamo Therapeutics' operational performance or stock valuation. No immediate action is warranted based solely on this filing.
Key Players & Entities
- SANGAMO THERAPEUTICS, INC. (company) — the registrant
- 7000 Marina Blvd., Brisbane, California 94005 (dollar_amount) — former principal executive offices address
- 501 Canal Blvd., Richmond, California 94084 (dollar_amount) — new principal executive offices address
- January 19, 2024 (dollar_amount) — date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by Sangamo Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report a change in the principal executive offices address of Sangamo Therapeutics, Inc. from 7000 Marina Blvd., Brisbane, California 94005 to 501 Canal Blvd., Richmond, California 94084.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on January 19, 2024.
What was Sangamo Therapeutics, Inc.'s former address?
Sangamo Therapeutics, Inc.'s former address was 7000 Marina Blvd., Brisbane, California 94005.
What is Sangamo Therapeutics, Inc.'s new principal executive offices address?
Sangamo Therapeutics, Inc.'s new principal executive offices address is 501 Canal Blvd., Richmond, California 94084.
Does this filing indicate any changes in the company's management or compensatory arrangements?
No, despite 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' being listed as an Item Information category, the content of this specific 8-K filing only details the change of the company's principal executive offices address and does not provide information on changes in management or compensatory arrangements.
Filing Stats: 588 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2024-01-19 17:09:13
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share SGMO Nasdaq Global
- $429,820 — payments up to an aggregate maximum of $429,820 and $193,584, respectively (the "Retent
- $193,584 — to an aggregate maximum of $429,820 and $193,584, respectively (the "Retention Payments"
Filing Documents
- sgmo-20240119.htm (8-K) — 30KB
- 0001628280-24-001784.txt ( ) — 187KB
- sgmo-20240119.xsd (EX-101.SCH) — 2KB
- sgmo-20240119_def.xml (EX-101.DEF) — 14KB
- sgmo-20240119_lab.xml (EX-101.LAB) — 28KB
- sgmo-20240119_pre.xml (EX-101.PRE) — 15KB
- sgmo-20240119_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SANGAMO THERAPEUTICS, INC. Dated: January 19, 2024 By: /s/ SCOTT B. WILLOUGHBY Name: Scott B. Willoughby Title: Senior Vice President, General Counsel and Corporate Secretary